These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12777330)

  • 1. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.
    Feeman WE
    Circulation; 2003 May; 107(20):e199. PubMed ID: 12777330
    [No Abstract]   [Full Text] [Related]  

  • 2. Achieving greater reductions in cardiovascular risk: lessons from statin therapy on risk measures and risk reduction.
    Ballantyne CM
    Am Heart J; 2004 Jul; 148(1 Suppl):S3-8. PubMed ID: 15211326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy.
    Denke MA
    Circulation; 2005 Nov; 112(22):3368-70. PubMed ID: 16316961
    [No Abstract]   [Full Text] [Related]  

  • 4. [High-density lipoprotein: a new target in the battle against atherothrombotic disease].
    Hansen PR
    Ugeskr Laeger; 2006 Jan; 168(5):468-70. PubMed ID: 16472435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a better marker of cardiovascular risk than LDL cholesterol? Apolipoproteins B and A-I--new risk factors and targets for therapy.
    Walldius G; Jungner I
    Nutr Metab Cardiovasc Dis; 2007 Oct; 17(8):565-71. PubMed ID: 17631989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is..
    Sniderman AD
    Circulation; 2005 Nov; 112(22):3366-7. PubMed ID: 16316960
    [No Abstract]   [Full Text] [Related]  

  • 7. Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2009 Aug; 104(4):548-53. PubMed ID: 19660610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.
    Ruel IL; Lamarche B; Mauger JF; Badellino KO; Cohn JS; Marcil M; Couture P
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2600-7. PubMed ID: 16224048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for optimizing lipid management.
    Ballantyne CM
    Postgrad Med; 2004 Sep; 116(3 Suppl):13-20. PubMed ID: 19667671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-density lipoprotein lowering in type 2 diabetes mellitus: how to know how low to go.
    Sniderman AD
    Curr Opin Endocrinol Diabetes Obes; 2007 Apr; 14(2):116-23. PubMed ID: 17940429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association of apolipoprotein B and low density lipoprotein with cardiovascular risk factors in the Thai population.
    Krittayaphong R; Chotinaiwatarakul C; Kangkagate C; Bhuripanyo K; Mahanonda N
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S1-7. PubMed ID: 17722296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B.
    Stein EA; Sniderman A; Laskarzewski P
    Am J Cardiol; 2005 Nov; 96(9A):36K-43K; discussion 34K-35K. PubMed ID: 16291013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Semiologic value of LDL cholesterol and apolipoprotein B in risk of atherosclerosis].
    Frey J; Couderc R
    Ann Biol Clin (Paris); 1998; 56(5):517-20. PubMed ID: 9769517
    [No Abstract]   [Full Text] [Related]  

  • 16. Interrelationships between human apolipoprotein A-I and apolipoproteins B-48 and B-100 kinetics using stable isotopes.
    Welty FK; Lichtenstein AH; Barrett PH; Dolnikowski GG; Schaefer EJ
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1703-7. PubMed ID: 15242863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of antiatherogenic L-aspartate and L-glutamate on serum lipoproteins cholesterol and apolipoproteins A-1 and B in rabbits fed with high cholesterol diet.
    Yanni AE; Perrea DN; Yatzidis HA
    Nutr Metab Cardiovasc Dis; 2005 Jun; 15(3):161-5. PubMed ID: 15955463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).
    Williams K; Sniderman AD; Sattar N; D'Agostino R; Wagenknecht LE; Haffner SM
    Circulation; 2003 Nov; 108(19):2312-6. PubMed ID: 14581403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced lipoprotein testing: recommendations based on current evidence.
    Lau JF; Smith DA
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):1-31. PubMed ID: 19217510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel.
    Barter PJ; Ballantyne CM; Carmena R; Castro Cabezas M; Chapman MJ; Couture P; de Graaf J; Durrington PN; Faergeman O; Frohlich J; Furberg CD; Gagne C; Haffner SM; Humphries SE; Jungner I; Krauss RM; Kwiterovich P; Marcovina S; Packard CJ; Pearson TA; Reddy KS; Rosenson R; Sarrafzadegan N; Sniderman AD; Stalenhoef AF; Stein E; Talmud PJ; Tonkin AM; Walldius G; Williams KM
    J Intern Med; 2006 Mar; 259(3):247-58. PubMed ID: 16476102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.